Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

The global synthetic biology market is anticipated to reach USD 31.52 billion in 2029 from USD 12.33 billion in 2024, with a ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...

PRNewswire/ -- "According to the latest BCC research study, the demand for Global Oncology Pharmaceuticals Market increased ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

Merck & Co. Inc.'s stock fell 3% Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to charges stemming from deals with partners Curon ...

Concurrently, Merck & Co. (MRK) lowered its sales outlook despite topping third quarter estimates, sending the stock lower. Julie Hyman and Brad Smith report more on these two pharma companies ...